Literature DB >> 10378636

The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer.

M J Johnson1, M W Sproule, J Paul.   

Abstract

The prevalence of venous thromboembolism (VTE) in cancer patients has been estimated as up to 15% antemortem, and higher (over 50% in pancreatic tumours) postmortem owing to the asymptomatic nature of many episodes of VTE. We investigated the prevalence of deep venous thrombosis (DVT) in a population of 298 hospice inpatients with advanced cancer. They were screened for the presence of DVT using light reflection rheography; 258 (86.6%) patients were evaluable for DVT, which was found in 135 (52%; 95% confidence interval 46-58). Factors associated (multivariate analysis) with the presence of DVT were: poor mobility, reduced serum albumin level and higher serum urea. A DVT risk assessment index was calculated using these variables. The three highest categories all had significant rates of DVT and, although the lowest category had a low rate of DVT, it accounted for less than 10% of all patients tested. DVT is common in patients with advanced cancer. It was found to be significantly associated with the above variables, but a combined index was of limited clinical application. In view of the number of patients identified with DVT, repeated small pulmonary emboli may be responsible for more symptoms than previously recognized in cancer patients.

Entities:  

Mesh:

Year:  1999        PMID: 10378636     DOI: 10.1053/clon.1999.9023

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  19 in total

Review 1.  The hypercoagulable state of malignancy: pathogenesis and current debate.

Authors:  Graham J Caine; Paul S Stonelake; Gregory Y H Lip; Sean T Kehoe
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

2.  Predictors of anticoagulation in hospice patients with lung cancer.

Authors:  Holly M Holmes; Kevin T Bain; Ali Zalpour; Ruili Luo; Eduardo Bruera; James S Goodwin
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

Review 3.  Venous thromboembolism and cancer: a systematic review.

Authors:  Celso Arrais Rodrigues; Renata Ferrarotto; Roberto Kalil Filho; Yana A S Novis; Paulo M G Hoff
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

Review 4.  Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?

Authors:  Ingrid Pabinger; Julia Riedl
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 5.  Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review.

Authors:  Hanno Riess; Piet Habbel; Anja Jühling; Marianne Sinn; Uwe Pelzer
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

6.  Stroke as a first manifestation of ovarian cancer.

Authors:  Andreas Borowski; Ali Ghodsizad; Emmeran Gams
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

Review 7.  The challenges of managing cancer related venous thromboembolism in the palliative care setting.

Authors:  S Noble
Journal:  Postgrad Med J       Date:  2007-11       Impact factor: 2.401

Review 8.  Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?

Authors:  A Maraveyas; M Johnson
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

9.  A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services.

Authors:  Robin R Hill; Kerri D Martinez; Thomas Delate; Daniel M Witt
Journal:  J Thromb Thrombolysis       Date:  2008-03-13       Impact factor: 2.300

10.  FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.

Authors:  Gareth O Griffiths; Sarah Burns; Simon I Noble; Fergus R Macbeth; David Cohen; Timothy S Maughan
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.